|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,030.60 INR | -2.85% |
|
+1.29% | +9.45% |
| 25/02 | Indo Borax & Chemicals Limited Appoints Shashikant Bharuka as the Chief Financial Officer Effective March 6, 2026 | CI |
| 10/02 | Ajanta Pharma Ltd issues clarification on media report | RE |
| Capitalization | 38TCr 409.2Cr 357.69Cr 323.15Cr 309.13Cr 562.26Cr 584.47Cr 3.86TCr 1.53TCr 18TCr 1.54TCr 1.5TCr 65TCr | P/E ratio 2026 * |
35.7x | P/E ratio 2027 * | 30.5x |
|---|---|---|---|---|---|
| Enterprise value | 37TCr 399.75Cr 349.42Cr 315.68Cr 301.99Cr 549.26Cr 570.96Cr 3.77TCr 1.49TCr 18TCr 1.5TCr 1.47TCr 64TCr | EV / Sales 2026 * |
6.88x | EV / Sales 2027 * | 6.06x |
| Free-Float |
33.52% | Yield 2026 * |
1.1% | Yield 2027 * | 1.27% |
Last Transcript: Ajanta Pharma Limited
| 1 day | -2.85% | ||
| 1 week | +1.29% | ||
| Current month | +1.23% | ||
| 1 month | +3.78% | ||
| 3 months | +13.94% | ||
| 6 months | +17.51% | ||
| Current year | +9.45% |
| 1 week | 2,852.4 |  | 3,228 |
| 1 month | 2,830 | | 3,228 |
| Current year | 2,654.5 | | 3,228 |
| 1 year | 2,327.3 | | 3,228 |
| 3 years | 1,131.7 | | 3,485 |
| 5 years | 1,061.77 | | 3,485 |
| 10 years | 550 | | 3,485 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | - | |
| Chief Executive Officer | 54 | 21/12/2009 | |
| Director of Finance/CFO | 61 | 23/04/1998 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | 01/01/1996 | |
| Chairman | 79 | 31/12/1979 | |
| Director/Board Member | 71 | 21/12/2009 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.85% | +1.29% | +19.40% | +148.40% | 409.2Cr | |
| -1.30% | +0.12% | +7.02% | +88.83% | 4.67TCr | |
| -0.14% | +9.39% | +43.71% | +174.51% | 3.64TCr | |
| -1.91% | +1.05% | +310.42% | +1,413.73% | 1.2TCr | |
| -0.72% | -0.49% | -10.07% | +50.29% | 1.15TCr | |
| -1.20% | -0.78% | +2.58% | +94.32% | 985.53Cr | |
| -0.06% | +3.11% | +73.30% | +52.74% | 846.93Cr | |
| +0.44% | 0.00% | +37.31% | +119.05% | 797.62Cr | |
| +1.18% | -6.27% | +43.08% | -17.01% | 695.72Cr | |
| -3.80% | +2.18% | +54.48% | +409.73% | 662.29Cr | |
| Average | -1.04% | +1.32% | +58.12% | +253.46% | 1.51TCr | |
| Weighted average by Cap. | -0.89% | +2.51% | +47.84% | +222.72% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 5.37TCr 58Cr 51Cr 46Cr 44Cr 80Cr 83Cr 548.23Cr 217.26Cr 2.57TCr 218.07Cr 213.46Cr 9.27TCr | 6.08TCr 66Cr 57Cr 52Cr 50Cr 90Cr 94Cr 620.56Cr 245.92Cr 2.91TCr 246.84Cr 241.62Cr 10TCr |
| Net income | 1.06TCr 11Cr 10Cr 9.07Cr 8.68Cr 16Cr 16Cr 108.35Cr 43Cr 507.51Cr 43Cr 42Cr 1.83TCr | 1.25TCr 13Cr 12Cr 11Cr 10Cr 19Cr 19Cr 127.15Cr 50Cr 595.57Cr 51Cr 50Cr 2.15TCr |
| Net Debt | -874.5Cr -9.45Cr -8.26Cr -7.47Cr -7.14Cr -13Cr -14Cr -89Cr -35Cr -417.8Cr -35Cr -35Cr -1.51TCr | -985.9Cr -11Cr -9.32Cr -8.42Cr -8.05Cr -15Cr -15Cr -100.56Cr -40Cr -471.02Cr -40Cr -39Cr -1.7TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/26/13 | 3,030.60 ₹ | -2.85% | 1,54,564 |
| 12/26/12 | 3,119.50 ₹ | +2.34% | 2,97,692 |
| 11/26/11 | 3,048.20 ₹ | +1.61% | 1,06,740 |
| 10/26/10 | 2,999.90 ₹ | +2.16% | 1,23,027 |
| 09/26/09 | 2,936.40 ₹ | -1.86% | 1,08,824 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AJANTPHARM Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition